| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20210347823
- Publication Date: November 11, 2021
- Appl. No: 17/277783
- Application Filed: September 19, 2019
- Assignees: Massachusetts Institute of Technology (Cambridge, MA, US), Fundação Universidade Federal do ABC - UFABC (Federal University of ABC Foundation) (Santo André, BR)
- Claim: 1. An antimicrobial peptide comprising the amino acid sequence of any one of SEQ ID NOs: 2-383.
- Claim: 2. The antimicrobial peptide of claim 1, wherein the antimicrobial peptide comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or SEQ ID NO: 21.
- Claim: 3. The antimicrobial peptide of claim 1, wherein the antimicrobial peptide consists of the amino acid sequence of any one of SEQ ID NOs: 2-383.
- Claim: 4. The antimicrobial peptide of claim 3, wherein the antimicrobial peptide consists of the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or SEQ ID NO: 21.
- Claim: 5. A composition comprising the antimicrobial peptide of any one of claims 1-4, optionally further comprising a pharmaceutically acceptable carrier.
- Claim: 6. A method of treating a microbial infection comprising administering, to a subject in need of such treatment, a therapeutically effective amount of the antimicrobial peptide of any one of claims 1-4 or the composition of claim 5.
- Claim: 7. The method of claim 6, wherein the subject is a mammal.
- Claim: 8. The method of claim 6 or claim 7, wherein the subject is human.
- Claim: 9. The method of any one of claims 6-8, wherein the antimicrobial peptide or the composition is administered orally, intravenously, intramuscularly, subcutaneously, or topically.
- Claim: 10. The method of any one of claims 6-9, wherein the microbial infection comprises a bacterial, fungal, algal, viral, or protozoan infection.
- Claim: 11. The method of claim 10, wherein the microbial infection comprises a bacterial infection, wherein the bacterial infection is a Gram-positive bacterial infection.
- Claim: 12. The method of claim 11, wherein the bacterial infection comprises a Gram-positive bacterium selected from the group consisting of a Micrococcus luteus bacterium, a Staphylococcus aureus bacterium, a Staphylococcus epidermidis bacterium, a Bacillus megaterium bacterium, and an Enterococcus faecium bacterium.
- Claim: 13. The method of claim 12, wherein: (a) the bacterium is a Micrococcus luteus bacterium, and wherein the Micrococcus luteus bacterium is strain A270; (b) the bacterium is a Staphylococcus aureus bacterium, and wherein the Staphylococcus aureus bacterium is strain ATCC29213 or ATCC12600; (c) the bacterium is a Staphylococcus epidermidis bacterium, and wherein the Staphylococcus epidermidis bacterium is a strain ATCC12228; or (d) the bacterium is a Bacillus megaterium bacterium, and wherein the Bacillus megaterium bacterium is a strain ATCC10778.
- Claim: 14. The method of any one of claims 10-14, wherein the microbial infection comprises a bacterial infection, wherein the bacterial infection is a Gram-negative bacterial infection.
- Claim: 15. The method of claim 14, wherein the bacterial infection comprises a bacterium selected from the group consisting of an Escherichia coli bacterium, an Enterobacter cloacae bacterium, a Serratia marcescens bacterium, a Pseudomonas aeruginosa bacterium, a Klebsiella pneumoniae bacterium, and an Acinetobacter baumannii bacterium.
- Claim: 16. The method of claim 15, wherein: (a) the bacterium is an Escherichia coli bacterium, and wherein the Escherichia coli bacterium is a strain SBS 363 or BL21; (b) the bacterium is an Enterobacter cloacae bacterium, and wherein the Enterobacter cloacae bacterium is a strain ®-12; (c) the bacterium is a Serratia marcescens bacterium, and wherein the Serratia marcescens bacterium is a strain ATCC4112; or (d) the bacterium is a Pseudomonas aeruginosa bacterium, and wherein the Pseudomonas aeruginosa bacterium is a strain PA14 or PA01.
- Claim: 17. The method of any one of claims 10-16, wherein the microbial infection comprises a fungal infection, wherein the fungal infection comprises a pathogenic yeast.
- Claim: 18. The method of claim 17, wherein the pathogenic yeast is selected from the group consisting of Candida albicans and Candida tropicalis.
- Claim: 19. The method of claim 18, wherein: (a) the yeast is Candida albicans, wherein the Candida albicans is strain MDM8; or (b) and yeast is Candida tropicalis, wherein the Candida tropicalis is strain IOC4560.
- Current International Class: 07; 61; 61
|
